Serum lysozyme activity in children with acute leukemia

Area of Science:

• Biochemistry
• Pediatric Oncology
• Immunology

Background:

• Serum lysozyme activity is a potential biomarker in various diseases.
• Acute leukemia in children encompasses several subtypes with distinct clinical and biological features.

Purpose of the Study:

• To investigate serum lysozyme activity in children diagnosed with acute leukemia.
• To assess the diagnostic and therapeutic monitoring value of serum lysozyme levels in pediatric acute leukemia.

Main Methods:

• Serum samples were collected from children with acute leukemia (acute lymphatic leukemia, acute myelogenous leukemia, monomyelocytic leukemia) and healthy controls.
• Lysozyme activity in serum was quantified using a standardized assay.

Main Results:

• Children with acute lymphatic leukemia (ALL) exhibited significantly reduced serum lysozyme levels at diagnosis and relapse, with levels normalizing during remission and after therapy cessation.
• Children with acute myelogenous leukemia showed normal lysozyme levels, while those with monomyelocytic leukemia presented with elevated levels prior to treatment.
• Serum lysozyme levels demonstrated variability across different subtypes of childhood acute leukemia.

Conclusions:

• Serum lysozyme activity is a valuable indicator for diagnosing acute lymphatic leukemia in children.
• Monitoring serum lysozyme levels can help evaluate the efficacy of therapeutic interventions in pediatric acute leukemia.
• Lysozyme activity may serve as a prognostic marker, with distinct patterns observed in different leukemia subtypes.